Acute Leukemia Diagnosis and Treatment

Introduction to AML and ALL

The National Comprehensive Cancer Network recommends that Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) be distinguished based on their cell lineage of origin, as this determines different treatment approaches, prognosis, and age distribution patterns 1, 2
AML originates from hematopoietic stem/progenitor cells of the myeloid lineage, while ALL arises from lymphoid progenitor cells, subdivided into B-cell and T-cell lineages 1, 2, 3

The American College of Hematology states that AML is the most common acute leukemia in adults, representing approximately 80% of adult acute leukemias, with a median age at diagnosis in the 60s 3
Myeloblasts in AML typically show myeloperoxidase (MPO) positivity on cytochemical staining, which is a key distinguishing feature 4
ALL represents 75-80% of acute leukemias in children but only 20% in adults, with a median age at diagnosis of 13 years 3, 5

AML expresses myeloid markers including CD13, CD33, CD117, and MPO, according to the National Comprehensive Cancer Network 4, 2
B-cell ALL expresses CD19, CD22, CD79a, and commonly CD10, while T-cell ALL shows cytoplasmic or surface CD3, along with variable expression of CD1a, CD2, CD5, CD7 1, 2
TdT (terminal deoxynucleotidyl transferase) is characteristically positive in ALL but negative in mature B-cell ALL 1, 2

The National Comprehensive Cancer Network recommends that both AML and ALL require ≥20% blasts in bone marrow for diagnosis, with exceptions for specific recurrent cytogenetic abnormalities 3, 5, 6
Comprehensive flow cytometric immunophenotyping is essential to determine lineage (lymphoid vs myeloid) and cannot be reliably determined by morphology alone 1, 4, 2

ALL in children frequently shows hyperdiploidy and t(12;21)/TEL-AML1, both associated with favorable outcomes, according to the National Comprehensive Cancer Network 1, 2, 5
Philadelphia chromosome t(9;22)/BCR-ABL is present in 25% of adult ALL and confers poor prognosis 1, 2, 5

The American College of Hematology states that ALL predominates in children with cure rates approaching 80% with current treatment regimens 3, 8
AML is primarily an adult disease with much lower cure rates, particularly in older adults, and prognosis varies widely based on cytogenetics, molecular markers, and patient age 1, 2

The National Comprehensive Cancer Network recommends that ALL requires 2-3 years of multi-agent chemotherapy with CNS prophylaxis, while AML typically involves shorter intensive induction and consolidation cycles 6
The distinction between AML and ALL is absolutely critical for treatment selection, as regimens are completely different and non-interchangeable 4, 7
Patients should be treated at specialized centers with expertise in acute leukemia management, according to the National Comprehensive Cancer Network 3, 5